ESTEVE and TerSera Therapeutics have announced that ESTEVE will acquire TerSera’s Infusion Specialty Therapies Business Unit (IST). This acquisition will aid ESTEVE grow its presence in the U.S. market with two specialized drugs and a team of sales, marketing, and medical professionals.
TerSera's IST unit includes two key medications: Prialt® (used for severe chronic pain) and Quzyttir® (an injectable antihistamine for treating hives). Prialt® is the only FDA-approved non-opioid treatment for certain types of chronic pain, and ESTEVE currently markets it in Europe. Quzyttir® is the first FDA-approved injectable antihistamine for hives and is approved for both adults and children.
As part of this deal, ESTEVE will get the global rights to Quzyttir® (except in China) and will have full rights to Prialt® worldwide.
According to coherent market insights, the Pharmaceutical Market is expected to grow at a CAGR of 8.1% during 2025 to 2032. Currently, the market is at USD 1.81 Tn in 2025 and is expected to be around USD 3.12 Tn by 2032. This major growth trajectory is driven by the rising healthcare demands, advancements in drug development, and increasing investments in biopharmaceutical research worldwide, positioning the market for robust expansion over the forecast period.
Staffan Schüberg, ESTEVE's Chief Executive Officer stated: "We are excited to welcome the Infusion Specialty Therapies Business Unit and look forward to welcoming TerSera's talented team to ESTEVE. This acquisition perfectly aligns with our strategic vision of providing highly specialized solutions where there is a significant unmet medical need. By adding Quzyttir® to our portfolio and expanding to the US market with Prialt®, we not only strengthen our expertise in highly specialized therapies but also accelerate our expansion in the United States—the world's largest pharmaceutical market."
"ESTEVE has been our long-term partner for Prialt® in Europe. Their expertise and core areas of focus make them the ideal future owner for IST." said Edward Donovan, Chief Executive Officer of TerSera. "We believe this transaction provides an excellent home for Prialt® and Quzyttir® to continue the strong momentum we have established with these medicines, while we sharpen our focus on our core therapeutic areas of oncology and rare disease."
Source:
Newsroom: TerSera Therapeutics
Company: TerSera Therapeutics
